Market: NMS |
Currency:
Address:
📈 RAIN Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
-
-
Upside/Downside from Analyst Target:
-
-
Broker Call:
-
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
<0%
-
Net Income Growth Range (1Y):
<0%
-
Revenue Growth Range (1Y):
-
-
Upcoming Earnings Date:
-
💰 Dividend History
No dividend history available.
📅 Earnings & EPS History for RAIN
| Date | Reported EPS |
|---|
| 2023-11-09 | -0.19 |
| 2023-08-10 | -0.61 |
| 2023-05-11 | -0.56 |
| 2023-03-09 | -0.7 |
| 2022-11-10 | -0.68 |
| 2022-08-04 | -0.66 |
| 2022-05-04 | -0.66 |
| 2022-03-03 | -0.68 |
| 2021-11-10 | -0.7 |
| 2021-08-10 | -0.39 |
| 2021-05-25 | -1.93 |
| 2021-04-23 | - |
📰 Related News & Research
-
Encore Medical IPO: Innovative PFO Closure Device Targets $1.5B Stroke & $100B Migraine Markets | Investment Opportunity & Clinical Trials Overview 2491018
April 5, 2026
Encore Medical, Inc. IPO: Investor-Grade Analysis, Financial...
-
Adaptin Bio, Inc. 2025 Annual Report: Pioneering Brain Cancer Therapies and Novel Drug Delivery Technologies
April 2, 2026
Adaptin Bio, Inc. 2025 Annual Report Detailed Investor Artic...
-
Update on First-Time Director Training Requirement for JEP Holdings Ltd.: Completion Status and Next Steps 1
April 1, 2026
JEP Holdings Ltd. Provides Key Update on Director Training R...
-
NeOnc Technologies: Innovative Drug Delivery Platforms and Pipeline for Brain Cancer and CNS Disorders
March 31, 2026
NeOnc Technologies Holdings, Inc. (NTHI) 2025 Annual Report ...
-
WRAP Technologies 2026 10-K: Integrated Non-Lethal Public Safety Solutions, BolaWrap, VR Training, and Risk Factors Analysis
March 27, 2026
Wrap Technologies, Inc. 2025 Annual Report: Key Highlights a...
-
Tonix Pharmaceuticals Begins Phase 1 Study of Intranasal Oxytocin (TNX-1900) for Migraine and Craniofacial Pain Treatment
March 26, 2026
Tonix Pharmaceuticals Announces First Participant Dosed in P...
-
Acumen Pharmaceuticals Reports 2025 Financial Results and Advances Alzheimer’s Drug Pipeline with Phase 2 ALTITUDE-AD Study and Enhanced Brain Delivery Program
March 26, 2026
Acumen Pharmaceuticals Reports 2025 Full-Year Financial Resu...
-
Sunrise Shares Holdings Ltd. Director Datuk Ng Completes Requisite Training Under Catalist Rules (March 2026)
March 25, 2026
Sunrise Shares Holdings Ltd. - Director Training Update ...
-
InMed Pharmaceuticals Reports Positive INM-901 Data in Human Brain Organoid Models for Alzheimer’s Disease Program 12
March 23, 2026
InMed Pharmaceuticals Reports Positive Preclinical Data for ...
-
Swarmer, Inc. Prices $15 Million IPO on Nasdaq to Expand Drone Autonomy Software for Ukraine Operations
March 19, 2026
Swarmer, Inc. Announces Pricing of Initial Public Offering: ...
🔍 View more Reports
